ACRS:NSD-Aclaris Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.40

Change

+0.06 (+0.39)%

Market Cap

USD 0.91B

Volume

0.21M

Avg Analyst Target

USD 31.50 (+104.55%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.68 (-1.05%)

USD138.04B 230.41 184.41
BNTX BioNTech SE

-0.86 (-0.27%)

USD68.59B 51.85 43.53
REGN Regeneron Pharmaceuticals, Inc

-3.28 (-0.56%)

USD62.50B 16.70 12.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.86 (-0.92%)

USD52.51B 19.34 13.17
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

-0.52 (-0.17%)

USD31.96B N/A N/A
GMAB Genmab A/S

-0.11 (-0.25%)

USD28.97B 32.86 3.81
SGEN Seagen Inc

+0.85 (+0.58%)

USD26.51B 40.76 35.56
RPRX Royalty Pharma plc

-0.28 (-0.73%)

USD23.39B 31.76 14.58
ALNY Alnylam Pharmaceuticals, Inc

-0.27 (-0.15%)

USD21.23B N/A N/A

ETFs Containing ACRS

Symbol Name Weight Mer Price(Change) Market Cap
DWMC AdvisorShares Trust - Adv.. 0.00 % 1.32 %

+0.94 (+2.63%)

USD8.90M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 138.02% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 138.02% 96% A 97% A+
Trailing 12 Months  
Capital Gain 581.42% 99% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 581.42% 99% A+ 98% A+
Trailing 5 Years  
Capital Gain -21.83% 46% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.83% 46% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 184.85% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 184.85% 94% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 585.01% 4% F 3% F
Risk Adjusted Return 31.60% 57% F 49% F
Market Capitalization 0.91B 71% C- 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.96 21% F 18% F
Price / Cash Flow Ratio -23.49 80% B- 81% B-
EV/EBITDA 0.05 87% B+ 97% A+
Management Effectiveness  
Return on Equity -75.77% 35% F 22% F
Return on Invested Capital -85.83% 23% F 9% F
Return on Assets -22.69% 52% F 16% F
Debt to Equity Ratio 28.29% 35% F 52% F
Technical Ratios  
Short Ratio 3.66 51% F 36% F
Short Percent 11.38% 22% F 16% F
Beta 0.62 83% B 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector